Online Supplementary Table 2: Proportion of patients by inclusion criteria (Safety set*)

	Total (N = 936)	Unilaterally treated (n = 823)	Bilaterally treated (n = 113)
Unilaterally treated			
VA <2/10	735 (78.5)	735 (89.3)	0
No VA <2/10, previous treatment with ranibizumab on any eye	71 (7.6)	71 (8.6)	0
No VA <2/10, no previous treatment with ranibizumab on any eye	14 (1.5)	14 (1.7)	0
VA <2/10, but missing diagnosis of nAMD	3 (0.3)	3 (0.4)	0
Bilaterally treated			
Both eyes VA <2/10	31 (3.3)	0	31 (27.4)
Only one eye VA <2/10, previous treatment with ranibizumab on any eye	6 (0.6)	0	6 (5.3)
Both eyes no VA <2/10, previous treatment with ranibizumab on any eye	3 (0.3)	0	3 (2.7)

Only one eye VA <2/10, no previous treatment with ranibizumab on any eye	14 (1.5)	0	14 (12.4)
Both eyes no VA <2/10, no previous treatment with ranibizumab on any eye	3 (0.3)	0	3 (2.7)
Unilaterally treated + fellow			
First eye VA<2/10, fellow eye VA <2/10	23 (2.5)	0	23 (20.4)
First eye VA<2/10, fellow eye no VA <2/10	29 (3.1)	0	29 (25.7)
First eye no VA<2/10 and with previous treatment with ranibizumab, fellow eye no VA <2/10	3 (0.3)	0	3 (2.7)
First eye no VA<2/10, fellow eye VA<2/10, previous treatment with ranibizumab on any eye	1 (0.1)	0	1 (0.9)

*Consisted of all enrolled patients who signed the informed consent, received at least one dose of study drug and had at least one post-baseline safety assessment.

nAMD, neovascular age-related macular degeneration; VA, visual acuity